Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.45 |
| ▸ | CDK8 | P49336 | 2/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.45 |
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | PRKACA | P17612 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | CLK2 | P49760 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | PRKX | P51817 | 2/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.45 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18129637 | 0.92 | CAMKK2 (0.53) | L3MBTL1DYRK1ACDK8DYRK1BCHEK1 | |
| SCHEMBL18129648 | 0.92 | L3MBTL1 (0.46) | L3MBTL1DYRK1ACDK8DYRK1BCHEK1 | |
| SCHEMBL18129722 | 0.92 | DYRK1A (0.51) | L3MBTL1DYRK1ACDK8DYRK1BCHEK1 | |
| SCHEMBL18129786 | 0.90 | L3MBTL1 (0.46) | L3MBTL1DYRK1ACDK8DYRK1BCHEK1 | |
| SCHEMBL18129522 | 0.88 | CAMKK2 (0.43) | DYRK1ADYRK1BCHEK1MAP4K4PIM1 | |
| SCHEMBL18129752 | 0.88 | ALDH1A1 (0.46) | L3MBTL1DYRK1ACDK8DYRK1BCHEK1 | |
| SCHEMBL18129486 | 0.86 | TNIK (0.52) | L3MBTL1DYRK1ACDK8DYRK1BCHEK1 | |
| SCHEMBL18129763 | 0.86 | L3MBTL1 (0.47) | L3MBTL1DYRK1ACDK8DYRK1BCHEK1 | |
| SCHEMBL18129659 | 0.86 | L3MBTL1 (0.47) | L3MBTL1DYRK1ACDK8DYRK1BCHEK1 | |
| SCHEMBL18129514 | 0.86 | L3MBTL1 (0.48) | L3MBTL1DYRK1ACDK8DYRK1BCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239873-B2 | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-03-26 | — | — | US | claimed |
| US-20160297815-A1 | 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-13 | — | — | US | claimed |
| US-10239873-B2 | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-03-26 | — | — | US | disclosed |
| US-10239873-B2 | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-03-26 | — | — | US | disclosed |
| US-20160297815-A1 | 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-13 | — | — | US | disclosed |
| US-20160297815-A1 | 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297815-A1 | 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TANK, NFKBIA, TBK1 | L3MBTL1 568/4885DYRK1A 1134/4885CDK8 75/4885 |
| US-10239873-B2 | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | NFKBIA, TANK, TBK1 | L3MBTL1 502/4885DYRK1A 1148/4885CDK8 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.